GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 6 [US11091464B2] | EDG-5506 | EDG5506
Compound class:
Synthetic organic
Comment: Sevasemten (EDG-5506) is an oral small molecule that inhibits fast skeletal muscle myosin ATPase [1], with the intention of behaviour as a muscle stabiliser for the treatment of dystrophinopathies.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| EDG-5506 is in clinical development as a potential treatment for muscular dystrophies, including Duchenne and Becker subtypes. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | Phase 2 Interventional | Edgewise Therapeutics, Inc. | ||
| NCT05540860 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | Phase 2 Interventional | Edgewise Therapeutics, Inc. | ||
| NCT06066580 | Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | Phase 2 Interventional | Edgewise Therapeutics, Inc. | ||
| NCT06100887 | Phase 2 Study of EDG-5506 in Children and Adolescents with Duchenne Muscular Dystrophy Previously Treated with Gene Therapy (FOX) | Phase 2 Interventional | Edgewise Therapeutics, Inc. | ||